1.66 +0.02 (1.22%)
After hours: 5:17PM EDT
|Bid||1.62 x 34100|
|Ask||1.70 x 2900|
|Day's Range||1.61 - 1.72|
|52 Week Range||1.50 - 6.99|
|Beta (3Y Monthly)||2.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.50|
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included leaders in e-commerce, smartphones and footwear. Bearish calls included a struggling conglomerate ...
The law firm of Kirby McInerney LLP is investigating potential claims against Geron Corporation (“Geron” or the “Company”) (GERN). This investigation concerns whether Geron has violated federal securities laws and/or engaged in other unlawful business practices. On September 27, 2018, Geron announced that “Janssen Biotech, Inc. (Janssen) has terminated the 2014 Collaboration and License Agreement (CLA) with the Company.
HENDERSON, NV / ACCESSWIRE / September 28, 2018 / One stem cell play we like a lot is BioRestorative Therapies, Inc., (BRTX) a life sciences company focused on stem cell-based therapies. They recently ...
NEW YORK, NY / ACCESSWIRE / September 28, 2018 / Rxi Pharmaceuticals saw its shares soaring on Thursday as the company presented a poster entitled, "The Use of Self-delivering RNAi to Enhance NK Cell Cytotoxicity," at the 16th Annual Discovery on Target Conference. Geron shares were going in the opposite direction and crashed hard after Wall Street learned that its collaboration with Johnson & Johnson has come to an end. RXi Pharmaceuticals Corporation shares were up a little over 28% at the close on Thursday.
RADNOR, Pa., Sept. 27, 2018-- Kaskela Law LLC is investigating claims on behalf of investors of Geron Corporation. The investigation concerns whether Geron and certain of its officers and/or directors ...
Stocks that moved substantially or traded heavily Thursday: Apple Inc., up $4.53 to $224.95 An analyst for JPMorgan Chase said Apple stock could rise more than 20 percent by late 2019. Carnival Corp., ...
In the first full trading session after the Fed decided to raise rates, the action wasn’t as clear-cut as it seemed during the first hours of the day. Tech popped, while the overall market moved higher. However, some of the air came out of those gains as the day went on, as stocks ended higher but with less conviction than in morning trade. Here are our top stock trades going into the end of the week.Top Stock Trades for Tomorrow #1: Bed Bath & Beyond (BBBY)
NEW YORK , Sept. 27, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Geron Corporation ("Geron" or ...
NEW YORK , Sept. 27, 2018 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) has been investigating claims on behalf of investors of Menlo park, California -based Geron Corporation ("Geron" ...
U.S. stock benchmarks opened tentatively higher Thursday as investors digested the Federal Reserve's third interest hike in 2018 at its Wednesday gathering and as Wall Street absorbed a wave of economic reports, including an update to second-quarter gross domestic product. The Dow Jones Industrial Average traded flat at 26,382, the S&P 500 index gained 0.1% at 2,910, while the Nasdaq Composite Index advanced 0.4% at 8,024. Markets slumped late Wednesday after the Fed lifted interest rates by a quarter-percentage point to a range of 2% to 2.25%, as expected, and signaled one more rate increase in December may be ahead. Meanwhile, investors watched a parade of data, including jobless claims, which rose less than expected in the latest week, though they remain near multidecade lows. Orders for durable goods rose 4.5%, faster than had been expected. U.S. real gross domestic product for the second quarter rose at a 4.2% annualized rate, unchanged from the earlier estimate, the Commerce Department said. In corporate news, shares of Geron Corp. plummeted after a collaboration deal with Janssen was terminated, as did those for Bed Bath & Beyond Inc. , which tumbled after it reported earnings and revenue that missed expectations. Wall Street may keep one eye trained on a Senate hearing of Supreme Court Justice nominee Brett Kavanaugh, who is contending with allegations of sexual misconduct.
A stellar year for Geron Corp. investors went up in smoke Thursday as shares plummeted on news that Johnson & Johnson will end a licensing partnership and return rights to the biotech company’s sole product candidate. Geron slid as much as 76 percent as the market opened, dropping to $1.99 at 9:44 a.m. in New York. The move wiped out $750 million in market value, which is more than the total value ascribed to a third of the companies in the Nasdaq Biotechnology Index.